Podcast
Rheumnow Podcast
Hosted by Dr. Cush · EN
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
64episodes
Episodes
Newest firstAll episodes
ICYMI: Great Lectures; Great Presentations
2w ago00:27:45Tap to summarizeDr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.
Transcribe →Generic Tofacitinib (6.26.2026)
3w ago00:30:23Tap to summarizeDr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.
Transcribe →
DERM on RheumNow (June 2026)
3w ago00:17:43Tap to summarizeThe Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: - Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs - TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr - BE BOLD: Bimekizumab Beats Risankizumab (LB0001) –H2H trial bimekizumab vs risankizumab in PsA for 24 weeks. At week 16; BKZ better than RZB, p=0.0058). This advantage was maintained out to week 24 (55% vs 44%; p 0.0001). - RA-BRIDGE and RA-BRANCH: FDA mandated study of the risk of venous thromboembolic events (VTE) taking baricitinib (BARI) or TNF inhibitors. The incidence rate was 0.79/100 PY for BARI combined versus 0.51/100 PY for TNFi. The hazard ratio was 1.606 (95% CI 0.969–2.660), with the upper CI exceeding the pre-specified NI margin of 1.8. Baricitinib (neither dose) was associated with a higher risk of MACE (HR 1.06), all-cause mortality (HR 0.97), arterial thromboembolism (HR 1.27), or opportunistic infections (HR 1.25). - Probiotics in Psoriatic Arthritis. (POS0290) 66 PsA patients randomized to receive either placebo or probiotic containing lactobacillus and bifidobacterium strains for 12 weeks. This trial proves no significant effect with oral probiotic supplementation in PsA. - CLE and smoking. Smoking reduces efficacy of antimalarials & worsens dz activity & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ - Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B
Transcribe →Do You Zoster Vaccinate? (6.19.2026)
4w ago00:29:24Tap to summarizeDr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
Transcribe →
RheumNow EULAR 2026 Rheumatology Round Up
Jun 1200:56:02Tap to summarizeDrs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the EULAR 2026 meeting in London.
Transcribe →
EULAR 2026 RA Topic Panel
Jun 1100:54:22Tap to summarizeJoin Drs. Bella Mehta, Jack Cush, Janet Pope, and Jon Kay for a focused conversation on the latest in rheumatoid arthritis care from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what’s shaping RA practice right now.
Transcribe →
CAR-T Topic Panel EULAR 2026
Jun 1000:38:02Tap to summarizeJoin Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.
Transcribe →
EULAR 2026 PsA Update What's Changing in Psoriatic Arthritis Care?
Jun 900:48:42Tap to summarizeJoin Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. This focused conversation explores new clinical data, evolving treatment strategies, and practical approaches to managing PsA in everyday practice. From advances in biologic and targeted therapies to ongoing challenges in diagnosis, disease monitoring, and patient care, the panel shares key insights and take-home messages that every rheumatology clinician should know. Tune in for expert perspectives, clinical pearls, and a comprehensive look at what's shaping the future of psoriatic arthritis management.
Transcribe →
RA Topic Podcast compilation
Jun 801:34:30Tap to summarize2026 EULAR Preview Beyond BMI: Altered Body Composition in Rheumatoid Arthritis CAR-T For Rheumatoid Arthritis This Is a Woman’s World: Women's Health in Rheumatic Disease Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Doctor's Orders or Patient's Choice: BACH study findings Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs Digital Patient Education in RA Making Methotrexate More Effective Are we failing in the treatment of RA-ILD? Using AI to Predict Progression to RA Treat to Target Works in Elderly Onset RA RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk Improving Referrals for Inflammatory Arthritis Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease
Transcribe →
PsA Topic Podcast compilation
Jun 801:36:32Tap to summarize2026 EULAR Preview Imaging in Subclinical Psoriatic Arthritis Dietary Interventions in PsA This Is a Woman’s World: Women's Health in Rheumatic Disease Impact of Synovial Biopsy-Driven Therapeutic Stratification in PsA Can We Stop PsA Before it Starts? BE BOLD: Going Where No PsA Trial Has Gone Before BMI Outranks Treatment in PsA Outcomes? Debate: Combination Therapies for Inflammatory Arthritis? Combination Biologics in PsA: MRI Findings from AFFINITY Combination Therapy in SpA The Case for Dual Pathway Blockade in Refractory PsA The AFFINITY Study: Combination Treatment in PsA PsA Potpourri: Probiotics & Head-to-Head Data Transition from Psoriasis to Psoriatic Arthritis MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial
Transcribe →